The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.
 
Goutam Chakraborty
No Relationships to Disclose
 
Rahim Hirani
No Relationships to Disclose
 
Subhiksha Nandakumar
No Relationships to Disclose
 
Teja Muralidhar Kalidindi
No Relationships to Disclose
 
Deborah Fidele
No Relationships to Disclose
 
Sai Harisha Rajanala
No Relationships to Disclose
 
Ying Zhang Mazzu
No Relationships to Disclose
 
Yuki Yoshikawa
No Relationships to Disclose
 
Lina E. Jehane
No Relationships to Disclose
 
Gwo-Shu Mary Lee
No Relationships to Disclose
 
Elisa de Stanchina
No Relationships to Disclose
 
Adam G. Sowalsky
No Relationships to Disclose
 
Michael J. Morris
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; Bayer; Curium Pharma; Curium Pharma; Endocyte; Johnson & Johnson; ORIC Pharmaceuticals
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Endocyte; Fujifilm
 
Heiko Schöder
Consulting or Advisory Role - Aileron Therapeutics
 
Naga Vara Kishore Pillarsetty
Stock and Other Ownership Interests - Amedisys; Ampio Pharmaceuticals; Bayer; Celldex; Immunogen; Ionis Pharmaceuticals; Lexicon; Madrigal Pharmaceuticals; Merrimack; OncoMed; Teva; Verastem; Viking Therapeutics; ZIOPHARM Oncology
Patents, Royalties, Other Intellectual Property - N Pillarsetty is a coinventor on intellectual property on Hsp90/epichaperome targeting agents that were developed at MSKCC and is currently licensed to Samus Therapeutics. N Pillarsetty has received financial royalties for his IP contributions that are li
 
Lorelei A Mucci
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Daniel Costin Danila
Honoraria - Angle; Astellas Pharma; AxImmune; Bayer; Clovis Oncology; Janssen Oncology; Pfizer; Pfizer; ScreenCell
Consulting or Advisory Role - Angle; Astellas Pharma; AxImmune; Bayer; Clovis Oncology; Janssen Scientific Affairs; Pfizer; Pfizer; Sanador
Research Funding - Genentech; Janssen Research & Development (Inst); Prostate Cancer Foundation
Patents, Royalties, Other Intellectual Property - GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER
Travel, Accommodations, Expenses - American Austrian Open Medical Institute; Astellas Pharma; Cambridge Healthtech Institute; Genzyme; Janssen Biotech; Janssen Scientific Affairs; Pfizer; Prostate Cancer Foundation; ScreenCell; Stop Cancer
 
Philip W. Kantoff
Leadership - Context Therapeutics
Stock and Other Ownership Interests - Context Therapeutics; Druggablity Technologies; Placon; Seer
Consulting or Advisory Role - Bavarian Nordic; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; OncoCellMDX; Progenity; Seer; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties